Oxurion N.V. (TBGNF)
Oxurion N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Leuven, BE. The stock last traded at $0.17, up 0.00% on the session, giving a market capitalisation of $433.7M. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -671.7%. Its beta of 0.35 implies it has historically moved less than the broad market.
Established in 1991 and headquartered in Leuven, Belgium, Oxurion NV operates as a biopharmaceutical company focused on innovating and commercializing medical solutions for various eye ailments globally. Its flagship product, JETREA, is approved for addressing vitreomacular adhesion and vitreomacular traction. The company's clinical pipeline includes THR-149, a plasma kallikrein inhibitor currently in Phase II development for diabetic macular edema (DME), and THR-687, an integrin antagonist also undergoing Phase II trials for DME. Oxurion maintains strategic collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company adopted its current name, Oxurion NV, in September 2018, having previously been known as ThromboGenics NV.
Oxurion N.V. is most often compared with the following Healthcare names: